Innovent Biologics (Suzhou) Co. Ltd.
4 clinical trials · 4 recruiting · INDUSTRY
Trials by Innovent Biologics (Suzhou) Co. Ltd.
RECRUITINGPhase 2NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.Enrolling: 15012 locations
Melanoma
RECRUITINGPhase 1NCT07295496
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese...
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.Enrolling: 641 location
Acute Gout Flare
RECRUITINGPhase 3NCT07113262
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration...
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.Enrolling: 1111 location
Thyroid Eye Disease
RECRUITINGPhase 1NCT06947408
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
This study is a randomized, double-blind, placebo-controlled multiple dose ascending study in healthy participants and patients with asthma. Healthy participants will be enrolled...
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.Enrolling: 601 location
Asthma